CYDY Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:58):

Stats
Dagens volum	1.48M
Gjennomsnittsvolum	2.20M
Markedsverdi	146.02M
EPS	$-0.0121 ( 2024-04-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.45
ATR14	$0.00200 (1.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Lalezari Jacob P	Buy	3 000 000	Non-qualified stock option (right to buy)
2024-02-01	Cohen Mitchell	Buy	0
2024-01-03	Migliarese Antonio	Buy	1 000 000	Non-qualified stock option (right to buy)
2024-01-03	Migliarese Antonio	Buy	630 222	Non-qualified stock option (right to buy)
2024-01-03	Migliarese Antonio	Buy	100 000	Non-qualified stock option (right to buy)

INSIDER POWER
73.53
Last 91 transactions
Buy: 23 178 436 \| Sell: 2 742 551

Volum Korrelasjon

Lang: 0.12 (neutral)

Kort: 0.57 (weak)

Signal:(49.275) Neutral

CytoDyn Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

CytoDyn Inc. Korrelasjon - Valuta/Råvare

0.50
( neutral )

0.45
( neutral )

0.00
( neutral )

-0.45
( neutral )

CytoDyn Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-175 000 (0.00 %)
EPS:	$-0.0954

FY	2023
Omsetning:	$0
Bruttogevinst:	$-175 000 (0.00 %)
EPS:	$-0.0954

FY	2022
Omsetning:	$266 000
Bruttogevinst:	$213 000 (80.08 %)
EPS:	$-0.430

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.270

Financial Reports:

No articles found.

CytoDyn Inc.

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.